Literature DB >> 16711011

Inhibition of metastatic progression of SSTR2 gene transfection mediated by adenovirus in human pancreatic carcinoma cells.

Yanping Feng1, Tao Huang, Jun Gao, Qing Chang, Renyi Qin.   

Abstract

The inhibition of metastatic progression of Somatostatin receptor type 2 (SSTR2) gene transfection mediated by adenovirus in human pancreatic carcinoma cells and the mechanisms involved in this effect were studied. The full-length human SSTR2 cDNA was introduced into the pancreatic cancer cell line BXPC-3 by adenovirus-mediated transfection. Stable expression of mRNAs and protein of SSTR2 was detected by RT-PCR and Western-blot. The Matrigel-coated Transwell was used to detect the migratory and invasive ability of SSTR2-expressing cells, Adv-GFP control cells and mock control cells. Furthermore, the expression of matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-2 (TIMP-2) was detected by RT-PCR in these cells. The stable expression of SSTR2 was detected in BXPC-3 transfected by Adv-GFP-SSTR2. A dramatic decrease of BXPC-3 expressing sst2 cells migrating through a Matrigel-coated filter was observed, as compared with Adv-GFP control and mock control cells (P < 0.01). Moreover, the expression of MMP-2 mRNA was significantly reduced in the SSTR2-expressing cells and conversely the expression of TIMP-2 mRNA was significantly increased in the SSTR2-expressing cells when compared with the Adv-GFP control and mock control (P < 0.01). The expression of reintroduced human SSTR2 gene in BXPC-3 cells by Adv-GFP-SSTR2 had the anti-migratory and anti-invasive effects, and the mechanisms involved in this effect may be due to the down-regulated expression of MMP-2 and up-regulated expression of TIMP-2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16711011     DOI: 10.1007/bf02828041

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  11 in total

Review 1.  Gene therapy progress and prospects: adenoviral vectors.

Authors:  J A St George
Journal:  Gene Ther       Date:  2003-07       Impact factor: 5.250

Review 2.  Oncological applications of somatostatin analogues.

Authors:  A V Schally
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

3.  Induction of a negative autocrine loop by expression of sst2 somatostatin receptor in NIH 3T3 cells.

Authors:  I Rauly; N Saint-Laurent; N Delesque; L Buscail; J P Estéve; N Vaysse; C Susini
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

4.  Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer.

Authors:  L Buscail; N Saint-Laurent; E Chastre; J C Vaillant; C Gespach; G Capella; H Kalthoff; F Lluis; N Vaysse; C Susini
Journal:  Cancer Res       Date:  1996-04-15       Impact factor: 12.701

Review 5.  Potential applications of tissue inhibitor of metalloproteinase (TIMP) overexpression for cancer gene therapy.

Authors:  A H Baker; M Ahonen; V M Kähäri
Journal:  Adv Exp Med Biol       Date:  2000       Impact factor: 2.622

Review 6.  Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials.

Authors:  Mark Bloomston; Emmanuel E Zervos; Alexander S Rosemurgy
Journal:  Ann Surg Oncol       Date:  2002-08       Impact factor: 5.344

7.  [Mechanisms of inhibition of growth of human pancreatic carcinoma implanted in nude mice by somatostatin receptor subtype 2].

Authors:  Kumar Manoj; Zheng-ren Liu; Rui Tian; Ren-yi Qin
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2004-05-02

8.  Anti-angiogenic effects of somatostatin receptor subtype 2 on human pancreatic cancer xenografts.

Authors:  Manoj Kumar; Zheng-Ren Liu; Laxmi Thapa; Ren-Yi Qin
Journal:  Carcinogenesis       Date:  2004-06-17       Impact factor: 4.944

9.  Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study.

Authors:  L Canobbio; F Boccardo; D Cannata; P Gallotti; R Epis
Journal:  Cancer       Date:  1992-02-01       Impact factor: 6.860

10.  Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer.

Authors:  T M Gress; F Müller-Pillasch; M M Lerch; H Friess; M Büchler; G Adler
Journal:  Int J Cancer       Date:  1995-08-09       Impact factor: 7.396

View more
  2 in total

Review 1.  Defining the cancer master switch.

Authors:  Courtney J Balentine; David H Berger; Shi-He Liu; Changyi Chen; John Nemunaitis; F Charles Brunicardi
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

2.  Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse.

Authors:  Jan K Hennigs; Julia Müller; Matti Adam; Joshua M Spin; Emilia Riedel; Markus Graefen; Carsten Bokemeyer; Guido Sauter; Hartwig Huland; Thorsten Schlomm; Sarah Minner
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.